DEF: Ovid Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

Ovid Therapeutics is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and improve stock marketability.

Summary

• Ovid Therapeutics is seeking stockholder approval for a reverse stock split of its common stock at a ratio between 1-for-10 and 1-for-40.
• The company aims to maintain its listing on the Nasdaq Global Market, which requires a minimum bid price of $1.00 per share.
• Ovid received a notification from Nasdaq on February 10, 2025, that it no longer met the minimum bid price requirement.
• The company has until August 11, 2025, to regain compliance.
• The reverse stock split is also intended to improve the marketability and liquidity of Ovid's common stock.
• The board will determine the specific ratio and timing of the reverse stock split if approved.
• The company is also seeking approval for the election of directors, executive compensation, and ratification of the selection of KPMG LLP as its independent registered public accounting firm.
• The Annual Meeting of Stockholders will be held virtually on July 9, 2025.
• The record date for the Annual Meeting is May 19, 2025.

Sentiment

Score: 5

Explanation: The document conveys a neutral sentiment. While the company is facing challenges with its stock price, it is taking proactive steps to address the issue. The reverse stock split is a common strategy, but its success is not guaranteed.

Positives

• Maintaining Nasdaq listing can improve market liquidity and investor confidence.
• Increased stock price may attract institutional investors and brokerage houses.
• Reverse stock split can provide flexibility for future business opportunities, including equity offerings and strategic transactions.
• The company is offering proxy materials over the internet to reduce environmental impact and costs.

Negatives

• Reverse stock split may not guarantee a sustained increase in stock price.
• The market price of the common stock may decrease due to factors unrelated to the reverse stock split.
• The reverse stock split may decrease the liquidity of the common stock and result in higher transaction costs.
• The effective increase in the authorized number of shares of common stock as a result of the Reverse Stock Split could have anti-takeover implications.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could result in delisting.
• Delisting could negatively impact market liquidity, stock price, and ability to obtain financing.
• The reverse stock split may not attract brokers and investors who do not trade in lower-priced stocks.
• The reverse stock split could increase the number of stockholders who own odd lots of fewer than 100 shares of common stock.

Future Outlook

The company is focused on regaining compliance with Nasdaq's minimum bid price requirement and improving the marketability and liquidity of its common stock. The company may be eligible for additional time to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(ii) by transferring to the Nasdaq Capital Market.

Management Comments

• On behalf of the Board of Directors and the employees of Ovid, we appreciate your investment in Ovid and urge you to cast your vote as soon as possible.
• The Board believes that the proposed Reverse Stock Split is a potentially effective means for us to maintain compliance with the Minimum Bid Price Requirement and to avoid, or at least mitigate, the likely adverse consequences of our common stock being delisted from Nasdaq by producing the immediate effect of increasing the bid price of our common stock.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. Many companies in the biotechnology and pharmaceutical industries, particularly those in the development stage, may experience stock price volatility and need to consider such measures to maintain listing requirements.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges have implemented reverse stock splits.
• Comparable companies that have recently undertaken reverse stock splits include XOMA Corporation (ratios of 1-for-10 and 1-for-15) and BioDelivery Sciences International (1-for-10).
• The success of a reverse stock split in maintaining listing and improving marketability varies depending on the company's underlying fundamentals and market conditions.

Related Party Transactions

• The Company provides indemnification for its directors and executive officers so that they will be free from undue concern about personal liability in connection with their service to the Company.
• The Company has also entered into indemnity agreements with certain officers and directors.

Stakeholder Impact

• Stockholders will be impacted by the reverse stock split, which will reduce the number of outstanding shares and may affect the stock price.
• Employees may be impacted by the company's ability to maintain its Nasdaq listing, which could affect the company's financial stability and future prospects.
• The company's ability to raise capital and pursue strategic transactions could be affected by its stock price and Nasdaq listing status.

Next Steps

• Stockholders will vote on the proposed reverse stock split and other proposals at the Annual Meeting on July 9, 2025.
• The board will determine the specific ratio and timing of the reverse stock split if approved by stockholders.
• The company will file a Certificate of Amendment with the Secretary of State of the State of Delaware if the board decides to implement the reverse stock split.
• The company will monitor its stock price to ensure compliance with Nasdaq's minimum bid price requirement.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, stockholders, proxy statement, Ovid Therapeutics, delisting, common stock, annual meeting, compliance